Summary
Definition
History and exam
Key diagnostic factors
- cefaleia episódica intenso
- náuseas e vômitos
- sensibilidade à luz e a ruídos
- impacto funcional
- sintomas de aura
- sensação latejante
Risk factors
- história familiar de enxaqueca
- sexo feminino e alterações hormonais
- má qualidade do sono
- estresse
- uso excessivo de medicamentos
- síndromes periódicas
Diagnostic investigations
1st investigations to order
- diagnóstico clínico
Investigations to consider
- ressonância nuclear magnética (RNM) cranioencefálica
- eletroencefalograma
- punção lombar
- velocidade de hemossedimentação (VHS) e proteína C-reativa
- tomografia computadorizada (TC) de crânio
Treatment algorithm
episódio agudo
≥1 enxaqueca significativa por semana
Contributors
Authors
Cristian Ionita, MD
Associate Professor of Clinical Pediatrics (Neurology)
Yale School of Medicine
New Haven
CT
Disclosures
CI declares that he has no competing interests.
Acknowledgements
Dr Christian Ionita would like to gratefully acknowledge Dr Nick Barnes, a previous contributor to this topic.
Disclosures
NB declares that he has no competing interests.
Peer reviewers
Kenneth Mack, MD, PhD
Medical Director
Mayo Clinic Pediatric Center
Rochester
MN
Disclosures
KM declares that he has no competing interests.
Tony McShane, MBBS
Consultant Paediatric Neurologist
John Radcliffe Hospital
Oxford
UK
Disclosures
TM declares that he has no competing interests.
Sandeep Jayawant, MBBS
Consultant Paediatric Neurologist
John Radcliffe Hospital
Oxford
UK
Disclosures
SJ declares that he has no competing interests.
Howard S. Jacobs, MD
Associate Professor
Co-Director Pediatric Headache Clinic
University of Maryland School of Medicine
Baltimore
MD
Divulgaciones
HSJ declares that he has no competing interests.
Agradecimiento de los revisores por pares
Los temas de BMJ Best Practice se actualizan de forma continua de acuerdo con los desarrollos en la evidencia y en las guías. Los revisores por pares listados aquí han revisado el contenido al menos una vez durante la historia del tema.
Divulgaciones
Las afiliaciones y divulgaciones de los revisores por pares se refieren al momento de la revisión.
Referencias
Artículos principales
Headache Classification Committee of the International Headache Society (IHS). The international classification of headache disorders, 3rd edition. Cephalalgia. 2018 Jan;38(1):1-211.Texto completo Resumen
Oskoui M, Pringsheim T, Billinghurst L, et al. Practice guideline update summary: pharmacologic treatment for pediatric migraine prevention. Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology and the American Headache Society. Neurology. 2019 Sep 10;93(11):500-9.Texto completo Resumen
Oskoui M, Pringsheim T, Holler-Managan Y, et al. Practice guideline update summary: acute treatment of migraine in children and adolescents. Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology and the American Headache Society. Neurology. 2019 Sep 10;93(11):487-99.Texto completo Resumen
Richer L, Billinghurst L, Linsdell MA, et al. Drugs for the acute treatment of migraine in children and adolescents. Cochrane Database Syst Rev. 2016 Apr 19;(4):CD005220.Texto completo Resumen
Artículos de referencia
Una lista completa de las fuentes a las que se hace referencia en este tema está disponible para los usuarios con acceso a todo BMJ Best Practice.
Diferenciales
- Cefaleia tensional
- Cefaleia por uso excessivo de medicamentos
- Cefaleia pós-traumática
Más DiferencialesGuías de práctica clínica
- Practice guideline update: acute treatment of migraine in children and adolescents
- Practice guideline update: pharmacologic treatment for pediatric migraine prevention
Más Guías de práctica clínicaFolletos para el paciente
Enxaqueca em crianças
Enxaqueca em crianças: medicamentos para prevenir as crises
Más Folletos para el pacienteInicie sesión o suscríbase para acceder a todo el BMJ Best Practice
El uso de este contenido está sujeto a nuestra cláusula de exención de responsabilidad